NYSE: GSK
Glaxosmithkline Plc Stock Forecast, Predictions & Price Target

Analyst price target for GSK

Based on 4 analysts offering 12 month price targets for Glaxosmithkline Plc.
Min Forecast
$40.50+19.29%%
Avg Forecast
$50.13+47.64%%
Max Forecast
$57.00+67.89%%

Should I buy or sell GSK stock?

Buy
Strong Buy
5 analysts 50%%
Buy
0 analysts 0%%
Hold
4 analysts 40%%
Sell
0 analysts 0%%
Strong Sell
1 analysts 10%%

Forecast return on equity

Is GSK forecast to generate an efficient return?
Company
157.53%%
Industry
65.68%%
Market
-6.64%%
GSK's Return on Equity is forecast to be high in 4 years (157.53%%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is GSK forecast to generate an efficient return on assets?
Company
22.54%%
Industry
15.48%%
Market
11.54%%
GSK is forecast to generate higher Return on Assets (22.54%%) than the US Drug Manufacturers - General industry average (15.48%%)
Forecast

GSK earnings per share forecast

What is GSK's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$2.98+58.68%%
Avg 2 year Forecast
$3.07+63.38%%
Avg 3 year Forecast
$3.21+70.93%%
GSK's earnings are forecast to grow at a rate of 19.38%% per year, which is not exceptional
Forecast

GSK revenue forecast

What is GSK's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$44.6B+32.13%%
Avg 2 year Forecast
$46.5B+37.88%%
Avg 3 year Forecast
$48.3B+43.07%%
GSK's revenue is forecast to grow at a rate of 12.68%% per year, which is not exceptional
Forecast

GSK earnings growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
19.38%%
Industry
18.94%%
Market
13.11%%
GSK's earnings are forecast to grow faster (19.38%% per year) than the US Drug Manufacturers - General industry average (18.94%%)
Forecast
GSK's earnings are forecast to grow faster (19.38%% per year) than the US market average (13.11%%)
Forecast

GSK revenue growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
12.68%%
Industry
6.35%%
Market
5.29%%
GSK's revenues are forecast to grow faster (12.68%% per year) than the US Drug Manufacturers - General industry average (6.35%%)
Forecast
GSK's revenues are forecast to grow faster (12.68%% per year) than the US market average (5.29%%)
Forecast

Glaxosmithkline Stock Forecast FAQ

The consensus among 10 Wall Street analysts covering (NYSE: GSK) stock is to Buy GSK stock.

Out of 10 analysts, 5 (50%%) are recommending GSK as a Strong Buy, 0 (0%%) are recommending GSK as a Buy, 4 (40%%) are recommending GSK as a Hold, 0 (0%%) are recommending GSK as a Sell, and 1 (10%%) are recommending GSK as a Strong Sell.
According to 4 Wall Street analysts that have issued a 1 year GSK price target, the average GSK price target is $50.13, with the highest GSK stock price forecast at $57.00 and the lowest GSK stock price forecast at $40.50.

On average, Wall Street analysts predict that Glaxosmithkline's share price could reach $50.13 by Oct 21, 2021. The average Glaxosmithkline stock price prediction forecasts a potential upside of 47.64%% from the current GSK share price of $33.95.
(NYSE: GSK) Glaxosmithkline's forecast annual earnings growth rate of 19.38%% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 18.94%%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 13.11%%.

Glaxosmithkline's earnings in 2019 is $4,645,000,000.On average, 6 Wall Street analysts forecast GSK's earnings for 2020 to be $16,029,621,520, with the lowest GSK earnings forecast at $15,706,877,462, and the highest GSK earnings forecast at $16,352,365,577. On average, 6 Wall Street analysts forecast GSK's earnings for 2021 to be $16,504,593,191, with the lowest GSK earnings forecast at $15,545,505,433, and the highest GSK earnings forecast at $17,051,644,368.

In 2022, GSK is forecast to generate $17,266,807,073 in earnings, with the lowest earnings forecast at $16,513,737,606 and the highest earnings forecast at $17,912,295,188.
(NYSE: GSK) Glaxosmithkline's forecast annual revenue growth rate of 12.68%% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.35%%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 5.29%%.

Glaxosmithkline's revenue in 2019 is $33,754,000,000.On average, 3 Wall Street analysts forecast GSK's revenue for 2020 to be $239,898,110,749,989, with the lowest GSK revenue forecast at $239,604,488,964,665, and the highest GSK revenue forecast at $240,062,408,991,496. On average, 3 Wall Street analysts forecast GSK's revenue for 2021 to be $250,333,308,294,114, with the lowest GSK revenue forecast at $245,090,223,499,649, and the highest GSK revenue forecast at $254,943,061,666,530.

In 2022, GSK is forecast to generate $259,759,333,582,233 in revenue, with the lowest revenue forecast at $254,013,020,874,340 and the highest revenue forecast at $266,418,226,628,809.
(NYSE: GSK) Glaxosmithkline's current Earnings Per Share (EPS) is $1.88. On average, analysts forecast that GSK's EPS will be $2.98 for 2020, with the lowest EPS forecast at $2.92, and the highest EPS forecast at $3.04. On average, analysts forecast that GSK's EPS will be $3.07 for 2021, with the lowest EPS forecast at $2.89, and the highest EPS forecast at $3.17. In 2022, GSK's EPS is forecast to hit $3.21 (min: $3.07, max: $3.33).
(NYSE: GSK) forecast ROE is 157.53%%, which is considered strong.
(NYSE: GSK) forecast ROA is 22.54%%, which is higher than the forecast US Drug Manufacturers - General industry average of 15.48%%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics